Our goal is to provide the highest level of care to all of our patients, and that includes offering novel treatments before they are widely available. If you are a cancer patient, you may be eligible for one of our current clinical trials.

Breast Cancer

Alliance AFT-25 (NCT 02926911)

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

 

Seattle Genetics SGNLVA-002 (NCT 03310957)

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

SWOG S1207 (NCT 01674140)

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Alliance A011104 (NCT 01805076)

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

NSAPB B51/RTOG 1304 (NCT 01872875)

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Alliance A011202 (NCT 01901094)

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Alliance A011106 (NCT 01953588)

ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: a phase III study

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Colon/Rectal Cancer

Abbvie M14-064 (NCT 03368859)

Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/ Oxaliplatin and Bevacizumab

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

NRG-GI002

A Phase II Clinical Trial Platform of Sensitization UtilizingTotal Neoadjuvant Therapy (TNT) in Rectal Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Leukemia

S1612 (NCT 03092674)

A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Pharmacyclics PCYC-1134M

informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Verastem VS-0145-224 (NCT 03370185)

A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Previously Treated with a Bruton’s Tyrosine Kinase Inhibitor (BTKi)

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Liver Cancer

Beigene BGB-A317-301 (NCT 03412773)

A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Lung Cancer

Abbvie M14-239 (NCT 03539536)

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Merck MK-3475-671 (NCT 03425643)

Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (KEYNOTE-671)

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Merck MK-3475-671 (NCT 03425643)

Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (KEYNOTE-671)

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Lymphoma

Pharmacyclics PCYC-1141-CA (NCT 02947347)

Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Genentech NP40126 (NCT 03467373)

A Phase 1B Study Evaluating RO7082859 in Combination with Rituximab (R) or Obinutuzumab (G) plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL)

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


NP30179 (NCT 03075696)

Open-Label, Phase I Study to Evaluate Safety Tolerability Pharmacokinetics of Escalating Doses of RO7082859 as Single Agent and in Combination with Obinutuzumab Admin after Fixed, Single Dose Pre-Treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Takeda C34008 (NCT 03357627)

A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

TG Therapeutics UTX-TGR-205 (NCT 02793583)

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Multiple Myeloma

Abbvie M13-367 (NCT 01794520)

A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Ovarian Cancer

U of C 13-1235 (NCT 02122185)

A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction with Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Pancreas Cancer

Abbvie M16-142

Creon® (pancrelipase) therapy for subjects with exocrine pancreatic insufficiency (EPI) due to pancreatic cancer: A double-blind, randomized, parallel design with 2 dose cohorts of pancrelipase in resected pancreatic cancer subjects and an open-label single dose cohort in non-resected pancreatic cancer subjects

If you are eligible and would like to participate, please contact the research staff at 708-915-4673 (HOPE) or send an email to clinicaltrials@ingalls.org.

Rafael Pharmaceuticals PANC003 (NCT 03504423)

A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Tumors

S1609 (NCT 02834013)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Abbvie M15-913 (NCT 03082209)

An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Boehringer Ingelheim 1381.1 (NCT 02952248)

An open-label, Phase I trial to determine the maximum-tolerated dose and investigate safety, pharmacokinetics, and efficacy of BI 754091 in patients with advanced solid tumours

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Exelixis XL184-021 (NCT 03170960)

Phase 1b Dose‑Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors 

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.

Seattle Genetics SGNTV-001

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.


Supportive Care

Dova Pharmaceuticals AVA-CIT-330 (NCT 03471078)

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers

If you are eligible and would like to participate, please contact the research staff at 708-915-HOPE (4673) or send an email to clinicaltrials@ingalls.org.